{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:20:31Z","timestamp":1777389631400,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.nmd.2025.105277","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T07:33:41Z","timestamp":1736840021000},"page":"105277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Management of presymptomatic juvenile patients with late-onset Pompe disease (LOPD)"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2602-5141","authenticated-orcid":false,"given":"M.","family":"Porcino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Usbergo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.G.","family":"Arena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-4827","authenticated-orcid":false,"given":"A.","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.nmd.2025.105277_bib0001","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/biom13091279","article-title":"A comprehensive update on late-onset pompe disease","volume":"13","author":"Labella","year":"2023","journal-title":"Biomolecules"},{"issue":"13","key":"10.1016\/j.nmd.2025.105277_bib0002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann Transl Med"},{"issue":"9\u201310","key":"10.1016\/j.nmd.2025.105277_bib0003","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"M\u00fcller-Felber","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2025.105277_bib0004","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-015-7664-0","article-title":"Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment","volume":"262","author":"Montagnese","year":"2015","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.nmd.2025.105277_bib0005","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Pompe Registry boards of advisors. Timing of diagnosis of patients with Pompe disease: data from the Pompe registry","volume":"161A","author":"Kishnani","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.nmd.2025.105277_bib0006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mus.21393","article-title":"Diagnostic criteria for late-onset (childhood and adult) Pompe disease","volume":"40","year":"2009","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2025.105277_bib0007","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van der Ploeg","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2025.105277_bib0008","doi-asserted-by":"crossref","first-page":"e16383","DOI":"10.1111\/ene.16383","article-title":"Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: european Pompe Consortium recommendation update 2024","author":"Schoser","year":"2024","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1016\/j.nmd.2025.105277_bib0009","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1111\/ene.13730","article-title":"Disease progression in a pre-symptomatically treated patient with juvenile-onset Pompe disease - need for an earlier treatment?","volume":"25","author":"Chien","year":"2018","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2025.105277_bib0010","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.nmd.2015.04.006","article-title":"208th ENMC International Workshop: formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26-28 September 2014","volume":"25","author":"Schoser","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.nmd.2025.105277_bib0011","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mus.23340","article-title":"New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy","volume":"45","author":"Angelini","year":"2012","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.nmd.2025.105277_bib0012","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/humu.23854","article-title":"Extension of the Pompe mutation database by linking disease-associated variants to clinical severity","volume":"40","author":"Ni\u00f1o","year":"2019","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.nmd.2025.105277_bib0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/humu.24148","article-title":"Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening","volume":"42","author":"de Faria","year":"2021","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.nmd.2025.105277_bib0014","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.nmd.2025.105277_bib0015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2025.105277_bib0016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.nmd.2025.105277_bib0017","first-page":"5","article-title":"LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population","volume":"87","author":"Musumeci","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.nmd.2025.105277_bib0018","first-page":"78","article-title":"Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD)","volume":"32","author":"Toscano","year":"2013","journal-title":"Acta Myol"},{"issue":"3","key":"10.1016\/j.nmd.2025.105277_bib0019","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1212\/WNL.0000000000002758","article-title":"Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness","volume":"87","author":"Lukacs","year":"2016","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.nmd.2025.105277_bib0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"12","key":"10.1016\/j.nmd.2025.105277_bib0021","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.nmd.2025.105277_bib0022","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.nmd.2025.105277_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163493","article-title":"Muscle MRI findings in childhood\/adult onset pompe disease correlate with muscle function","volume":"11","author":"Figueroa-Bonaparte","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.nmd.2025.105277_bib0024","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/mus.27099","article-title":"Skeletal muscle magnetic resonance imaging in Pompe disease","volume":"63","author":"D\u00edaz-Manera","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2025.105277_bib0025","first-page":"58","article-title":"Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy","volume":"3","author":"Gruhn","year":"2015","journal-title":"Mol Genet Metab Rep"},{"issue":"8","key":"10.1016\/j.nmd.2025.105277_bib0026","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s10072-020-04316-6","article-title":"Ultrasound assessment of diaphragm function in patients with late-onset Pompe disease","volume":"41","author":"Ruggeri","year":"2020","journal-title":"Neurol Sci."},{"issue":"11","key":"10.1016\/j.nmd.2025.105277_bib0027","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.nmd.2015.09.003","article-title":"Clinical and pathophysiological clues of respiratory dysfunction in late-onset Pompe disease: new insights from a comparative study by MRI and respiratory function assessment","volume":"25","author":"Gaeta","year":"2015","journal-title":"Neuromuscul Disord."},{"issue":"1","key":"10.1016\/j.nmd.2025.105277_bib0028","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1038\/s41467-024-52143-6","article-title":"Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease","volume":"15","author":"Tan","year":"2024","journal-title":"Nat Commun"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:26:36Z","timestamp":1741695996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"alternative-id":["S0960896625000045"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105277","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of presymptomatic juvenile patients with late-onset Pompe disease (LOPD)","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105277"}}